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Abstract
Recurrence and metastasis have been regarded as two of the
greatest obstacles for curing cancer. Cancer stem cell (CSC)
have been found. They contribute to cancer development with
the distinct feature of recurrence and resistance to the popular
treatments such as drugs and chemotherapy. In addition, re-
cent discoveries suggest that the epithelial mesenchymal tran-
sition (EMT) is an essential process in normal embryogenesis
and tissue repair, which is a required step in cancer metasta-
sis. Although there are many indications showing the connec-
tions between metastasis and stem cell, researches often stud-
ied them separately or at most bi-laterally, not in an integrated
way. In this study, we aim at exploring the global mechanisms
and interrelationship among cancer, development and metas-
tasis which are currently poorly understood. To start, we con-
structed a core gene regulatory network motif which contain
specific genes and microRNAs of CSC, EMT and cancer. We
uncovered seven distinct states emerged from the underlying
landscape. They are identified as Normal, Premalignant, Can-
cer, stem cell (SC), cancer stem cell (CSC), Lesion and Hy-
perlasia state. Given the biological definition of each state, we
also discussed the metastasis ability of each state. We show
how and which types of cells can be transformed to a can-
cer state and the connections among cancer, CSC and EMT.
The barrier height and flux of the kinetic paths are explored to
quantify how and which cells switch stochastically between
the states. Our landscape model provides a quantitative way
which reveals the global mechanisms of cancer, development
and metastasis.
Keywords:landscape, kinetic path, CSC, EMT, differ-
entiation, metastasis
1 Quick guide to equations and as-
sumptions
In a bio-chemical system, reactions will happen anytime. So
the variations of the system states must be a complex pro-
cess of dynamics. There are M reactions R1,R2, ...,RM of
the protein regulations. Each reaction R j corresponds to a
propensity function a j. a j(x)dt is defined as: to a given
X(t) = x, the probability of R j has reacted once within time
[t, t + dt). In general, it is hard to describe the propensity
function a j accurately. We can obtain an approximate de-
scription: a j(x) = c j∏Nk=1C
m jk
xk .
∏Nk=1C
m jk
xk is the probability of the molecular Sk will partic-
ipate in the reaction R j. The value of xk represents total num-
ber of Sk, and mk represents the number of reactants which
participate in the reaction. c j is the constant of chemical re-
action, which can obtain from experiments.
In our model, we use Gillespie algorithm[1] to obtain
the stochastic distribution time of protein binding/unbinding.
Due to intrinsic fluctuations and variations of the protein
molecule numbers in the cells, we explore the stochastic
dynamics time of each protein binding/unbinding steps and
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change the protein molecule numbers correspondingly as
c j∏Nk=1C
m jk
xk .
In order to describe the biological process precisely, we de-
fined a set of time scale parameters of each process. We used
the parameters g for protein synthesis rate and k for protein
degradation rate, h is the binding rate and f is the unbinding
rate of regulatory proteins to the target genes. The protein
synthesis rate is influenced by the regulated gene number and
regulated type. There are two regulated type: binding state
and unbinding state. If the protein has n binding site, the
protein will has 2n synthesis rates. The synthesis rate will
be increase by a factor of λa or decreased by a factor of λr,
respectively. If there are 2 binding sites one is activation the
other is repression, the 4 synthesis rates will be set as: g00, g01
= g00λa, g10 = g00λr, g11 = g00λaλr. We define the equilib-
rium constants: Xeq= f/h, the adiabatic parameter: ω = f/k.
The later is used to quantify the unbinding time of a protein
in its lifetime. If the value of ω is large, it means the reg-
ulation processes are relatively fast compared to the synthe-
sis/degradation which is sometimes termed as adiabatic. If
the value of ω is small, it means the regulation processes are
relatively slow. The protein switches on and off to the tar-
get gene relatively slowly which is non-adiabatic. Please see
the SupportInformation for details. In this work, we mainly
discussed the adiabatic case.
2 Introduction
Cell phenotypes change during the development of cellular
differentiations [2, 3]. Differentiation starts from an oosperm
which develops into a complex system of biont and continues
in adulthood as stem cells divide and generate differentiated
daughter cells when the tissue repair and cells regenerate[4].
Induced pluripotent stem cells (iPS) are a type of pluripotent
stem cells which provide the opportunity of the therapeutic
uses[5]. The adult cells have been reprogramed into pluripo-
tent stem cells in 2006 [6]. This is a significant step in the
stem cell and regenerative biology as the cell type switch-
ing can skip many intermediate steps. This lineage repro-
gramming technology may also have profound implications
for cancer biology.
Cancer has been one of the most deadly disease for human
beings. Studies show that there are multiple factors associ-
ated with the recurrence and metastasis which lead to cancer
fatal to human beings[7]. Many researches concentrate on
the origin of cancer being from the genetics (mutations)[8, 9].
The accumulation of mutations led to malignant transforma-
tion which was described as a disease of clonal evolution.
Through these mutation and selection, the cells acquire the
hallmarks of cancer[10, 11]. Some cells may acquire hypoxia
characteristic. Some cells may acquire fast-growing charac-
teristic. Some cells may develop new blood vessels and so on.
This is a widely accepted concept for understanding the gen-
eration of cancer. On the other hand, more and more observa-
tions have demonstrated that cancer should be thought of an
intrinsic state which emerges from the underlying gene reg-
ulation networks[12, 13]. The gene regulation network con-
trolled a series of cellular activity and biological processes.
The network can perform the regulation instructions which
may affect early events of cancer[14]. These network envi-
ronmental and epigenetic effects can result not only silencing
of tumor suppressors but also reactivating the silenced regions
which could prime subsequent events in the development of
cancer[15, 16].
Cancer stem cells (CSCs) can be defined as the cells
with the characteristics of cancerous and stem cell-like
features[17]. The CSCs are considered to be the seeds of can-
cer. Although cancer cells might be killed during the radia-
tion and chemotherapy, the CSCs as seeds of cancer can still
survive. This can explain the cancer recurrence after treat-
ments. Although the CSC theory has been reported as early as
1952[18], the importance of that had been realized recently.
CSCs have been found that they serve as the basis of cancer
developement, maintenance, metastasis and recurrence[19].
In general, the development/differentiation process is from
the primary stem cell and the reprogramming is vice versa
which is important to the tissue reengineering. The exam-
ple of cellular reprogramming is induced pluripotent stem
(or iPS) cells, which gives the hope for cell fate switching
and transformation[20]. However reprogramming often en-
counters cancer state which result to the transformed progeni-
tors acquiring self-renewal and cancerous characteristics[21].
One may encounter the CSCs. Furthermore, CSCs facilitate
the primary tumor cells to migrate from one location to an-
other which is a key step in the metastatic cascade.
EMT is an essential process, through which most adult tis-
sues maintain the migratory capacity in normal embryogen-
esis, wound healing and tissue repair[22]. CSCs can plant
into another organ also through the EMT process[23]. In the
EMT process, a set of transcription factors(TFs) induce the
early steps of metastasis[24]. Through the EMT-TFs, the dif-
ferentiated epithelial cells can obtain mesenchymal traits to
colonize foreign tissues and create new tumor site in distant
organs. Moreover, EMT process is also a trail for non-stem
cells turning into stem cell states. Experiments have observed
that inducing an EMT process during normal mammary ep-
ithelial cells differentiation can make a generation of mam-
mary epithelial stem-like cells[25]. This kind of experimen-
tal phenomena can be observed in both normal and cancerous
tissues[26]. Thereby, EMT is an important process which not
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only contribute to creating metastatic CSCs, but also has a
close relationship with CSCs[27].
Despite many evidences showing the connections between
the metastasis and stemness of the cell, or cancer and dif-
ferentiation/development [28], these are still rarely stud-
ied in an integrated way of cancer, metastasis and devel-
opment/differentiation. We aim to explore the connections
among cancer, development/differentiation and metastasis in
a systematic and quantitative way. We start by constructing
a core gene regulation network motif. In order to character-
ize the key points of the dynamic process, the specific genes
and microRNAs of cancer, CSC and EMT was included. In
this work, we quantified the underlying landscape of cancer,
metastasis and development/differentiation. Furthermore, we
include regulatory binding/unbinding information to make
the model more precise. Seven states emerged from the land-
scape which are quantified by the basins of attractions repre-
senting the Normal, Premalignant, Cancer, SC, CSC, Lesion
and Hyperplasia states. We define these states by the gene
expression level and the biological significance. We discuss
the metastasis ability of these states as well. There are three
kinetic paths from Normal to Cancer state. Two kinetic paths
which connect CSC state show the formation of cancer stem
cells from two sources. The optimal paths and barrier height
between the states can illustrate how and which cells will be
able to transform to cancer state and why cancer is so diffi-
cult to cure. This leads to a quantitative understanding of the
degree of difficulty in curing the cancer. Moreover, the quan-
tified landscape give us a portrait which uncover the dynamic
interrelationship of the biological process among CSCs, EMT
and cancer. Then we use global sensitivity analysis to discuss
which regulation is more sensitive for cancer curing which
can give a guide on clinical experiments of cancer. This work
can elucidate the origin of cancer, as well as the process of
cancer development/differentiation and metastasis. This has
clear clinical significance in helping to understand the CSC
basis of treatment response, therapeutic resistance, and can-
cer relapse.
3 Results and Discussion
3.1 Model Construction
To emphasize the characteristics of CSCs, EMT and cancer, a
core gene regulatory network motif covers specific genes and
micro-RNAs of the three aspects. As shown in Fig.1, MDM2
is an oncogene of cancer, P53 is a well known tumor sup-
pressor gene[29]. ZEB is an EMT activator gene which sup-
presses the stemness-inhibition of micro-RNA (mir-200)[30].
OCT4 is an essential gene which mediates phenotype self-
renewal and stemness[31]. mir-145 and mir-200 are two im-
portant microRNA which play vital roles in both CSC and
EMT regulation[32]. The arrows represent activation and the
short bars represent the repression.
3.2 Definition and metastasis ability of each
steady states and the kinetic paths of the
landscape
There are 6 nodes in our network motif. It is difficult for
us to visualize a 6-dimensional space. Thus we chose to
discuss three specific genes P53, ZEB and OCT4, reflect-
ing the cancer, EMT and development/differentiation (with
CSCs) aspects. P53 is a tumor suppressor gene. The cells
in normal function often with high gene expression level of
P53. Low gene expression level of P53 is a general char-
acteristics of cancer[29, 33]. OCT4 is a signature gene of
stem cell. Many studies show that OCT4 is critically in-
volved in the self-renewal and is a critical gene for cell dif-
ferentiation and reprogramming [34]. High gene expression
level of OCT4 means the cells are of self-renewing ability,
multi-differentiating potential, and strong proliferative abil-
ity. ZEB is a critical gene of EMT process. The expression of
ZEB can activate EMT process and EMT is a required step in
metastasis[35]. The gene expression level of ZEB is a metas-
tasis signature.
From Fig.2, we can see that there are seven states emerging
which are named as Normal, Premalignant, Cancer, SC, CSC,
Lesion and Hyperplasia, respectively. In Normal state, the
gene expression of P53 is high and the gene expression of
OCT4 and ZEB is low. This illustrates that if the cells stay
in normal state, they have a normal function. They do not
have the characteristics of stem-cells such as self-renewal or
reprogramming, and do not have the metastasis ability either.
The Lesion state has a low expression levels of P53, OCT4
and ZEB. Low gene expression level of OCT4 and ZEB indi-
cate that the cells do not have the characteristics of stem-cell
or metastasis ability. Low gene expression level of P53 il-
lustrate the cells do not have normal function which maybe
caused by inflammation, pH, hypoxic and so on[36].
In Hyperplasia state (the tumor state without metastasis),
compared with the Lesion state, the expression level of OCT4
is high and the expression level of P53 and ZEB are low.
High gene expression level of OCT4 implies that the cells
have the characteristics of stem-cells such as self-renewal or
reprogramming. Hyperplasia state can be seen as the accumu-
lated cell damage while the tissue which are inflamed starts
the self-repairing which helps to produce new cells to replace
the pathological cells. In this process, OCT4 is also a sig-
nificant player in self-repair and DNA replication[37]. Low
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gene expression level of ZEB indicates that the metastasis is
not significant. Low expression level of P53 indicates that
the cells are still in abnormal condition. Cells in the Lesion
and Hyperplasia states are both with a degree damage as the
gene expression level of P53 is low. In general, they can be
reversed to normal state by our self-healing system as the ex-
pression level of ZEB is low, the metastasis has not start yet.
In cancer state, the gene expression level of ZEB is high,
the gene expression level of OCT4 and P53 is low. As we
known, for the cells in cancer state, the P53 which is a tumor
suppressor gene is in low expression level but the metastasis
ability is obvious (high gene expression level of ZEB). More-
over, if the cancer cells are in the terminally differentiated
stage, they have lost the ability to proliferate or to alter its
destiny, the stemness ability is relatively low as well. So the
gene expression level of OCT4 is low.
The Premalignant state (tumor state with certain metasta-
sis) is a transition state between Normal and Cancer state. In
the Premalignant state, the expression level of P53 becomes
lower and the gene expression level of ZEB becomes higher
when the cells transform from Normal to Cancer state. That
means, when the cell state moves from Normal to Cancer, the
cancerization and metastasis become more and more signifi-
cant. As the metastasis ability of Premalignant state is inter-
mediate. It has certain metastasis capability which brides the
normal state and the complete cancer/metastasis state.
In the SC state, the gene expression level of P53 and OCT4
is high, ZEB is low. The SC state has the stemness activity
so the expression level of OCT4 is high. The expression level
of P53 is high and the expression of ZEB is low which means
the metastasis ability is not active.
In the CSC state (the tumor state with significant stemmed
and metastasis), the expression level of P53, OCT4 and ZEB
are all in the intermediate level. The cells are in the transition
between SC and Cancer state. The CSCs show up some char-
acteristics of cancerization and self-renewal (stemness) as the
gene expression level of P53 is lower and OCT4 is higher than
the Normal state. Moreover, the elevated gene expression of
ZEB shows that the cells have a certain ability of metastasis
between the SC and Cancer state.
For the landscape perspectives, there are several major ki-
netic paths we can quantitatively explore. When the expres-
sion level of ZEB increases, the paths from SC to CSC and
CSC to Cancer state become prominent. These two paths
illustrate that the formation of CSCs is roughly from two
sources. One route for generating CSCs is from the so-
matic stem cells with self-renewal capabilities which have
the potential to divide into both stem cells and specialized
somatic cells, which destined to stop proliferating or die[38].
If these stem cells are out of control for stopping division,
but still keeping the ability of self-renewal and differentia-
tion, they become cancer stem cells[39, 40]. Another route
for generating CSCs is that a minor proportion of cancer
cells have the capacity of self-renewal and differentiation
in their progeny[32]. Many experiments have demonstrate
that the terminally differentiated cancer cells can gain SCs
properties under specific epigenetic conditions[17]. These
stem cell-like cancer cells drive the cell growth and metas-
tasis are considered as cancer stem cells. Many reports
have shown that cancer cells undergoing EMT can obtain
stem cell-like characteristics[41], which demonstrate the con-
nection between EMT and CSC. These have been found in
hematopoietic[42] and solid tumor such as brain[43] and
breast cancer[44]. These two paths driving the CSCs have
the capacity of self-renewal, differentiation and migration in-
dependently. The kinetic paths of the landscape view can il-
lustrate the dynamic transitions of SC, CSC and cancer. Due
to these diversifications, the CSCs show a series headache
ability of drug resistance and recurrence.
From the landscape view, we can also see that there is not
only one kinetic path from Normal to Cancer state. There
are at least three major paths. One is from SC to CSC to
Cancer state. The SCs can gain cancer characteristics and
become CSCs. Recently, some studies tracing of CD133+
cells provided direct evidence that SCs were susceptible to
cancerous transformation[45, 46]. The CSCs inherit many
characteristics of SCs, including self-renewal and differenti-
ation. Moreover, the CSCs with cancerization characteristics
such as uncontrollable growth and metastasis. The CSCs can
asymmetricly divided into cancer cells and CSCs[4]. So the
CSCs can be seen as the seeds of cancer cells. Another path
is from Normal to Premalignant to Cancer state. This can
be seen as a cancerous process. On this path, the gene ex-
pression level of P53 decreases and ZEB increases. This in-
dicates that the cells not only have pathologic change trend
but also have metastasis characteristics at the mean time. The
third one is from Normal to Lesion to Hyperplasia to Can-
cer state. This can be seen as a process which develops
from normal cells, going through lesion, gaining the ability
of proliferate(hyperplasia) then turning malignant, and even-
tually falling into Cancer state. Some experiments have show
that the lesion often happened before the hyperproliferative
changes[36]. The hyperplasia is accumulated to a certain de-
gree, cells process the ability of metastasis, transform to Can-
cer state ultimately. These three paths would roughly answer
a central question in cancer biology, how and which cells can
be transformed to cancer. This helps us understanding why
cancer is so difficult to cure because the formation of paths.
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3.3 Barrier heights and flux of kinetic paths
We calculated the barrier heights and the flux of each kinetic
paths for further analysis. We know that the barrier heights
determine the stability of the states. The higher the barrier is,
the more difficult it is to transform from one cell type to an-
other. The barrier heights can also correlate with the switch-
ing frequency from one state to another.
Fig.3 shows that the barrier heights between Normal, Pre-
malignant, Cancer, SC, CSC, Lesion and Hyperplasia states.
In path1, the barrier height from SC to CSC state is 6.0189
and from CSC to Cancer state is 3.5048. We can describe the
carcinogenesis of stem cells a high barrier move difficult to
occur. It demands strong regulation and environmental con-
ditions to make the stem cells cancerous[17]. The cancer stem
cells differentiate to cancer cells with a much lower barrier is
a easy process as the CSCs can generate cancer cells progeny
when they divided. A cancer stem cell can be asymmetric di-
vided into a cancer cell and a cancer stem cell[4]. The barrier
height from SC to Normal is 6.0509 which is comparable to
the barrier from SC to CSC state. SC state has two choices: to
become normal differential cell or become cancer stem cell,
both with certain degree of difficulties. In adults, the somatic
stem cells are always dormant, it requires specified condition
to induce the stem cells to divide. On the other hand, repro-
gramming requires specific gene regulations. Therefore the
barriers for both the differentiation and reprogramming back
are relatively high. When the stem cells are activated the stem
cells are asymmetric divided into stem cells and normal so-
matic cells. It appears that at SC state, the cell can either
switch to differentiated cell or cancer stem cell. The paths
connect CSC to SC state and CSC to Cancer state with the
barriers of 3.0348 and 3.5048. It can illustrate that when the
cells stay in CSC state, they are both very unstable due to
the low barrier height and more likely to transform to Cancer
state or back to SC. The barrier height from Cancer to CSC
state is 9.11. That is also a high barrier which means it is dif-
ficult for the cancer cells to transform back to CSCs. Exper-
iments have revealed that there are only a minor proportion
of cancer cells having the capacity of self-renewal and differ-
entiation in their progeny[32]. Therefore, the switching from
cancer cells to CSCs is not very easy to be realized. We can
state that path1 has both the characteristics of stem cells and
metastasis. Cells going through path1 from normal state can
change stemness and metastasis, and eventually reach Cancer
state.
On path2, The barrier heights of Premalignant to Normal
state and Normal to Premalignant state are 3.2795 and 5.2719
respectively. The barrier height from Premalignant to Normal
state is lower than the barrier from Normal to Premalignant.
It illustrates that if the cell is in Normal state it is relative diffi-
cult to transform to Premalignant state. And if the cell stays in
Premalignant state, it is easier to reverse back to Normal state.
Moreover, the barrier height of Premalignant state to Cancer
and Cancer state to Premalignant are 1.3395 and 7.41 respec-
tively. It illustrates that the cell in Premalignant state with in-
termediate level of metastasis is much easier to transform to
Cancer state than reverse from Cancer state back to Premalig-
nant. The barriers between Premalignant state and Normal or
Cancer states are lower, so the cell state can transform to the
Normal or Cancer state relatively easily. The fatal fate of can-
cer is its uncontrolled diffusion and metastasis, if the cells are
in Cancer state, the metastasis is obvious. So the Premalig-
nant state with intermediate level of tumor and metastasis has
vital clinical significance of early diagnosis and prevention of
cancer as cells in Premalignant state can transform to Cancer
or reverse back to Normal state easily. Therefore, path2 has
the characteristics of metastasis. Cells going through path2
can reflect metastasis process as the Premalignant state is an
intermediate state of metastasis. The importance of Prema-
lignant state was discussed in our previous study[29].
In path3, we can see the barrier heights between Normal,
Lesion and Hyperplasia are 4.0419− 4.9682 and 4.7582−
6.2117. The barriers are not too high. It means that it is not
very difficult to transform from one to another. Experiments
have shown that the lesion is of common occurrence before
the hyperproliferative changes[36]. But the barrier heights
between Hyperplasia and Cancer is 6.4117− 8.11. It means
that transformation from Hyperplasia to Cancer or reverse
back from Cancer to Hyperplasia are both difficult and the
Cancer to Hyperplasia state is difficult to occur. That tells us
that it is not difficult for the cells transfer from one to another
state before the metastasis (transform to Cancer state). If the
cells have not reached metastasis, it is relatively easy to cure
(reverse to Normal state). And the cells become cancerous
due to hyperplasia is a difficult process but it is more diffi-
cult to escape from Cancer state to Hyperplasia as it needs
to overcome a very high barrier. Therefore, path3 reflects
the process of accumulated cell damages to metastasis. Cells
in path3 going through more and more pathological changes
and eventually reach Cancer state.
In Fig.3, we can see that the paths connect Cancer state to
CSC, Premalignant and Hyperplasia state are all with rela-
tive high barriers which are 9.11, 7.41 and 8.11 respectively.
These illustrate that the barriers of Cancer state are all very
high. So the cells in Cancer state are difficult to escape and
that can explain why the cancer are so difficult to cure.
We have also calculated the correlation of the transition
time and the barrier height. The correlation coefficient we
calculated is 0.80. As Fig.4 shows, the transition time and the
barrier height presenting basically the same trend.
We also compared the flux of the three paths (from Nor-
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mal to Cancer state and the reverse back). The flux of each
path can help us to figure out which path is more important
in cancer formation. According to the transition time and the
probability of each pathway, we can quantify the flux of each
path. The transition time in our work depends on the land-
scape topography. The barrier heights of each state can reflect
the landscape topography. The transition rate k of a pathway
is the reciprocal of transition time. The details and data can
be seen in the support Information. This method has been ap-
plied in our previous work[47]. The flux of the path from Nor-
mal→ SC→ CSC→ Cancer is 2.2157 ∗ 10−10. The proba-
bility of this path is 0.0719. The flux of the path from Normal
→ Premalignant → Cancer is 2.6227 ∗ 10−9. The probabil-
ity of this path is 0.8509. The flux of the path from Normal
→ Lesion → Hyperplasia → Cancer is 2.3813 ∗ 10−10. The
probability of this path is 0.0773. The flux and the proba-
bility of the path from Normal → Premalignant → Cancer
account for the vast majority of the three. So this path is
dominant for Normal to Cancer state transition. Therefore,
to prevent cancer formation, this is worthy attention and we
have demonstrated the importance of Premalignant state for
cancer prevention in our previous work[29].
In the same way, we can also quantify the flux from Cancer
to Normal state. The flux of the path from Cancer→ CSC→
SC→ Normal is 2.1830 ∗ 10−9. The probability of this path
is 0.4243. The flux of the path from Cancer→ Premalignant
→ Normal is 9.3693 ∗ 10−10. The probability of this path
is 0.1821. The flux of the path from Cancer → Hyperplasia
→ Lesion→Normal is 2.0245∗10−9. The probability of this
path is 0.3935. The flux of path1( from Cancer→ CSC→ SC
→ Normal) and path3 (Cancer→ Hyperplasia→ Lesion→
Normal) are very close which are higher than path2 (Cancer
→ Premalignant→ Normal). To reverse Cancer state back to
Normal, these two paths should be pay attention to. And the
flux and probability of Path1 is higher than Path3, so this path
is dominant for Cancer to Normal state transition. We need
to pay more attention on CSC for cancer curing.
These three paths can address a central question in cancer
biology, how and which cells can be transformed to cancer in
a quantitative way. The barrier heights can describe the basin
depths of the landscape and help us understanding the ten-
dency of the cells transformation from one state to another.
Furthermore, the barrier heights of Cancer state are all very
high, that means the cells in Cancer state are difficult to trans-
form to others. The presence of multiple cancer formation
paths can explain the various mechanisms of cancer forma-
tion and that is one of the reasons why cancer is difficult to
prevent. The flux of the paths can lead us to find out which
path is dominant in the cancer formation and help us describe
the difficulty of curing cancer in a quantitative way.
3.4 Finding key regulations by global sensitiv-
ity analysis of landscape topography
To get further insight of the cancer formation and curing, we
explored network motif to find the key regulations by global
sensitivity analysis on landscape topography. In the network
motif, each gene and regulation contributes to network dy-
namics. Variation the regulation strengths will influence the
barrier heights between attractor basins. Through this way we
can figure out which regulations are more sensitive for cancer
curing in the network motif.
Fig.5(A) and (B) display the variation of regulation
miR200a ZEB and regulation1 is miR200a ZEB in Fig.5(A).
Fig.5(C) and (D) display the variation of regulation OCT4→
OCT4 and regulation1 is OCT4→ OCT4 in Fig.5(C).
Fig.5(E) and (F) display the variation of regulation P53→ P53
and regulation1 is P53→ P53 in Fig.5(E). In Fig.5(A), (C) and
(E), the control regulations 2−13 are P53→ miR200, P53→
miR145, P53→ MDM2, miR145a ZEB, miR145a OCT4,
miR145a MDM2, ZEBa miR200, ZEBa miR145, ZEB→
ZEB, OCT4→ miR200, OCT4→ miR145 and MDM2a P53,
respectively.
In Fig.5(A) we increased the regulations strength to 1.5
times. We can see that, in regulation1(miR200a ZEB) the
barrier height from Premalignant state to Cancer state in-
creased significantly, and the barrier height from Cancer state
to Premalignant state slightly decreased. Although regulation
6 changed very significant too, we abandon it as it changed in
the same direction. As we know, the gene ZEB is an EMT ac-
tivator gene, when the gene expression level is high the metas-
tasis becomes obvious. So when we increased suppression
strength of ZEB, the expression level becomes lower than be-
fore which leads to the weaker metastasis than before. In
that case, the cell state moves from Premalignant to Cancer
state much more difficult than before, and moves from Can-
cer to Premalignant state easier which is beneficial to can-
cer recovery. In Fig.5(B), we varied the regulation strength
from 0.8−1.5 times. When the regulation strength becomes
smaller, the barrier height from Premalignant to Cancer state
decreased and the barrier height from Cancer to Premalig-
nant state increased. This could also illustrate the regulation
is associated with the variation of the barrier height between
Premalignant and Cancer state. This variation of regulation
miR200a ZEB can give the information of how to control the
metastasis.
In Fig.5(C) we increased the regulations strength to 1.3
times. OCT4 is a signature gene of stem cell. If the expres-
sion level of OCT4 is high, the stemness of the cell is obvious.
We can see that, when the regulation strength increased, the
expression level of OCT4 is increased, the barrier height from
Normal to SC state is decreased and the barrier height from
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SC to Normal state increased significantly. This means that
the cell in Normal state becomes easier to move to SC state,
and the cells in SC state becomes more difficult to move to
Normal state. In the meantime, the barrier height from Nor-
mal to Premalignant becomes lower than before, and the bar-
rier height from Premalignant to Normal become higher. This
indicates that the cell in Normal state is easier to become can-
cerous, and the cell in Premalignant becomes more difficult to
move back. These variation results are consistent with the ex-
periment induced pluripotent stem cells (iPS). Many studies
have pointed out that the cellular reprogramming of iPS often
lead to the cell with cancerous characteristics which eventu-
ally reaches to Cancer state[20, 21]. In Fig.5(D), when the
regulation strength decreased to 0.7 times, the barrier height
from Normal to Premalignant state is increased and the bar-
rier height from Premalignant to Normal state is decreased.
This indicates that the cells in Normal state are more stable,
and the cells in Premalignant state are more likely to trans-
form to Normal state. The barrier height from Normal to SC
state increased and the barrier height from SC to Normal state
decreased. That means the cells in Normal state are harder
to switch to SC state and the cells in SC state are more apt
to transform to Normal. The regulation OCT4→ OCT4 can
reflect the connection between the stem cells and metastasis.
This variation may help researchers finding treatments of can-
cer through the stem cell clue.
In Fig.5(E), we also increased the regulations strength to
1.3 times. We can see that the variation of regulation1 (P53→
P53) can lead the barrier height from Normal to SC state to
become higher and the barrier height from SC to Normal state
is lower. This indicates that when the expression level of P53
increasing, the cells in Normal state become more difficult to
transform to SC state and the cells in SC state is much easier
to transform to Normal state. Experiments have shown that
P53 is a major driving force for the differentiation of embry-
onic stem cells (ESCs). Spontaneous differentiation of hESCs
reduced significantly when P53 expression is decreased[48].
P53 also can provides an effective barrier for the generation of
stemness cells from terminally differentiated cells[49]. The
variation of regulation P53→ P53 can help us to realize the
importance of P53 not only for cancer and but also for stem
cell processes.
As we know P53 is a tumor suppressor which we can see
in Fig.5(F). When the regulation strength decreased to 0.9
times and P53 abundance reduced, the barrier height from
Normal to Premalignant state has barely changed, but the bar-
rier height from Premalignant to Normal state is increased
significantly. In this situation, the cells in Premalignant state
are more difficult to move back to Normal state. When
the regulation strength is increased to 1.1 times, the barrier
height from Normal to Premalignant state has no significant
change and the barrier height from Premalignant to Normal
becomes lower. That means the cells in Premalignant state
will be easier to Normal state. When the regulation strength
is increased to 1.2 and 1.3 times, the variation of the bar-
rier height between Normal and Premalignant are both only
slightly. When the concentration of P53 reaches a very high
level, its characteristic of tumor suppressor become less obvi-
ous and other characteristics are present such as inducing the
cells to apoptosis[50].
To see the variation clearly, we depict the landscape topog-
raphy of miR200a ZEB from regulation strength 1.0 to 1.5
times. In Fig.6, the depth of the basin of Premalignant state
increased significantly when the regulation strength increased
and the depth of the basin of Cancer state is decreased.
4 Conclusion
Cancer is a complex and fetal disease. The cancer has fea-
tures of metastasis, drug resistance and recurrence. These
are related to CSCs which leads the cancer to be a major
health threat of human being. Recent studies showed that
EMT plays a vital role to induce early step of metastasis and
is also a way for non-stem cells turning into stem cells. In
this study, we develop a dynamic model which includes spe-
cific genes and microRNAs for CSC, EMT and cancer, aim-
ing at uncovering the connections among cancer, metastasis
and development/differentiation through CSC, EMT and can-
cer. We quantify the underlying landscape to explore the can-
cer development/differentiation and metastasis. The origin
of cancer can then be elucidated. The kinetic paths and bar-
rier heights between each state can be quantified. The barrier
heights determine the stability of the state. Based on the bar-
rier heights, we can relate to the switching frequency of the
cells from one state to another. Multiple cancer formation
paths can be observed. The flux of each path (from normal
leading to cancer and the reverse back) is calculated by the
statistics of the path transitions. This is used to figure out
which path is more important in cancer formation and cancer
curing. This can also help us quantifying the degree of diffi-
culty in curing cancer. Furthermore, we use global sensitivity
analysis to find key regulations which are vital for cancer cur-
ing. Three regulations miR200a ZEB, OCT4→ OCT4 and
P53→ P53 are more sensitive to the cancer curing. This work
study the functional dynamics and physical mechanisms of
cancer development/differentiation and metastasis in a quan-
titative way. This can give us a guide in cancer clinical ther-
apy.
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Figure 1: The diagram for the core gene regulatory network mo-
tif which contain 6 nodes and 16 regulations (7 activations and 9
repressions, the arrows represent the activate regulations, the short
bars represent the repress regulations). The nodes of diamond shape
represent the microRNAs. The orange round ones represent the spe-
cific genes of cancer, the violet one represents the specific gene of
EMT, and the pink one represents the specific gene of CSC.
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Figure 2: The 3-dimensional landscape shows the Normal, Prema-
lignant, Cancer, SC, CSC, Lesion and Hyperplasia states and opti-
mal paths among those states.
11
Figure 3: The barrier heights between normal, premalignant, cancer,
sc, csc, lesion and hyperplasia states and optimal paths among those
states. Black arrows represent the barrier from one state to another.
The data marked on is the barrier height to overcome. The blue
arrows represent the kinetic paths from normal leading to cancer
state and the reverse back.
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Figure 4: The correlation of the transition time and barrier heights.
The y-axis represents the data of barrier height and the x-axis repre-
sents the data of transition time which have taken ln.
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AB
Figure 5: Variation rate of barrier height with regulation strength changed. P−C (C−P) denotes the barrier height from Premalignant
state to Cancer state (Cancer state to Premalignant state). N−P (P−N) denotes the barrier height from Normal state to Premalignant state
(Premalignant state to Normal state). N−SC (SC−N) denotes the barrier height from Normal state to SC state (SC state to Normal state).
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Figure 6: Variation of barrier height when the regulation strength changed from 1.0 to 1.5 times. Label L represents the Lesion state, Label
P represents the Premalignant state, Label C represents the Cancer state and the Label N represents the Normal state.
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